Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    gog-0127w
Show Display Options
Rank Status Study
1 Active, not recruiting Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Small Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Recurrent Cervical Cancer;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer
Interventions: Drug: veliparib;   Drug: topotecan hydrochloride;   Biological: filgrastim;   Biological: pegfilgrastim;   Other: laboratory biomarker analysis

Indicates status has not been verified in more than two years